Zydus Cadila receives DCGI nod for NAFLD drug Saroglitazar Mg in India
Non-Alcoholic Fatty Liver Disease (NAFLD) is a progressive disease of the liver, which starts with fat accumulation in the liver in patients who do not consume alcohol or take it in insignificant amounts, but have risk factors such as overweight or obesity, diabetes mellitus (high blood sugar), hypertension (high blood pressure) or dyslipidemia (abnormal blood lipids).
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: Alcoholism | Biotechnology | Diabetes | Diabetes Mellitus | Eating Disorders & Weight Management | Endocrinology | Fatty Liver Disease (FLD) | Hypertension | India Health | Liver | Liver Disease | Non-alcoholic Fatty Liver Diseases (NAFLD) | Obesity | Pharmaceuticals | Sugar | Urology & Nephrology